Prolia (denosumab) is a human IgG2 monoclonal antibody with affinity and specificity for human RANKL (receptor activator of nuclear factor kappa-B ligand).
Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, as defined by factors such as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, Prolia reduces the incidence of vertebral, nonvertebral and hip fractures.
Media Articles Related to Prolia (Denosumab)
Do Dollars Form the Backbone of Osteoporosis Recs? (CME/CE)
Source: MedPage Today OB/Gyn [2015.07.23]
(MedPage Today) -- Analysts assert bone health advocacy groups are funded and influenced by industry.
Kidney, bladder stones do not increase postmenopausal women's risk of osteoporosis
Source: Bones / Orthopedics News From Medical News Today [2015.07.13]
Postmenopausal women with kidney or bladder stones are not at increased risk for osteoporosis, but they do have about a 15 percent increased risk of another painful stone, physician-scientists...
Osteoporosis Pictures Slideshow: Super Foods for Your Bones
Source: MedicineNet estradiol Specialty [2015.04.24]
Title: Osteoporosis Pictures Slideshow: Super Foods for Your Bones
Created: 2/3/2009 12:00:00 AM
Last Editorial Review: 4/24/2015 12:00:00 AM
Thyroid Disease, Osteoporosis and Calcium
Source: MedicineNet Bone Density Scan Specialty [2014.12.01]
Title: Thyroid Disease, Osteoporosis and Calcium
Category: Doctor's Views
Created: 10/2/2001 12:00:00 AM
Last Editorial Review: 12/1/2014 12:00:00 AM
Osteoporosis Pictures Slideshow: Are Your Bones at Risk?
Source: MedicineNet Bone Density Scan Specialty [2014.09.09]
Title: Osteoporosis Pictures Slideshow: Are Your Bones at Risk?
Created: 4/23/2009 12:00:00 AM
Last Editorial Review: 9/9/2014 12:00:00 AM
Published Studies Related to Prolia (Denosumab)
Clinical Trials Express: fracture risk reduction with denosumab in Japanese
postmenopausal women and men with osteoporosis: denosumab fracture intervention
randomized placebo controlled trial (DIRECT). 
with osteoporosis compared with placebo... CONCLUSION: These results provide evidence of the efficacy and safety of
Delaying skeletal-related events in a randomized phase 3 study of denosumab
versus zoledronic acid in patients with advanced cancer: an analysis of data from
patients with solid tumors. 
myeloma... CONCLUSIONS: Denosumab was more effective in delaying or preventing SREs in
Superiority of denosumab to zoledronic acid for prevention of skeletal-related
events: a combined analysis of 3 pivotal, randomised, phase 3 trials. 
across three pivotal studies... CONCLUSION: Denosumab was superior to zoledronic acid in preventing SRE with
Responder analysis of the effects of denosumab on bone mineral density in men
receiving androgen deprivation therapy for prostate cancer. 
(lumbar spine (LS), femoral neck (FN) and total hip (TH)) and the distal radius... CONCLUSIONS: In men with prostate cancer receiving ADT, significantly higher BMD
Dose-response study of denosumab on bone mineral density and bone turnover
markers in Japanese postmenopausal women with osteoporosis. 
12 months in Japanese postmenopausal women with osteoporosis... CONCLUSIONS: Denosumab 60 mg could be an effective dose for Japanese
Clinical Trials Related to Prolia (Denosumab)
Treatment of Atraumatic Bone Marrow Edema With Denosumab and Teriparatide vs Placebo [Recruiting]
The etiology of bone marrow edema (BME) is still uncertain. Several studies report
therapeutic success with antiresorptive drugs.
This study investigates antiresorptive and osteoanabolic drugs versus placebo in BME
Denosumab for Prevention of Osteoporosis in Renal Transplant Recipients [Recruiting]
The primary objective of the study is to examine the effect of denosumab on total hip bone
mineral density (BMD) after one year of treatment in newly transplanted renal allograft
recipients. Secondary endpoints include BMD changes at the lumbar spine and the femoral
neck, changes in body height, changes in bone mineral metabolism parameters, incidence of
fractures, and allograft function at one year. Safety measurements include the occurrence of
rejection episodes, infectious complications, graft loss and mortality.
- Trial with medicinal product
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis - The ADAMO Trial [Recruiting]
The purpose of this study is to assess how effective and safe denosumab is in a population
of males with low bone mass at risk of fracture. The primary clinical hypothesis is that in
men with low bone mineral density, the mean percent change in lumbar spine bone mineral
density at 12 months in subjects receiving denosumab will be greater than in subjects
receiving placebo. Denosumab is a fully human monoclonal antibody with a high affinity for
Receptor Activator of Nuclear Factor-kB (RANK) Ligand that can bind and neutralize the
activity of human RANK Ligand similar to the action of endogenous osteoprotegerin.
Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium [Recruiting]
The purpose of this study is to determine the potential of denosumab to treat Hypercalcemia
of Malignancy in patients with elevated serum calcium who do not respond to recent treatment
with intravenous bisphosphonates by lowering corrected serum calcium = 11. 5 mg/dL (2. 9
millimoles /L) by day 10.
Reports of Suspected Prolia (Denosumab) Side Effects
Pain in Extremity (348),
Back Pain (330),
Osteonecrosis of JAW (169),
Bone Pain (161),
Hypocalcaemia (146), more >>